Gain Therapeutics Inc Total Assets
Gain Therapeutics Inc total assets. Based on the latest financial reports, Gain Therapeutics Inc (GANX) holds total assets worth $18.74 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Gain Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Gain Therapeutics Inc (2018–2025)
Total assets of Gain Therapeutics Inc from 2018 to 2025. This chart illustrates how Gain Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See latest Gain Therapeutics Inc stock price today for real-time trading data and today's change.
Gain Therapeutics Inc - Asset Composition Analysis
Gain Therapeutics Inc Total Assets Breakdown (December 2025)
Gain Therapeutics Inc total assets breakdown as of December 2025. Gain Therapeutics Inc's total assets of $18.74 Million consist of 97.5% current assets and 2.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.3% |
| Accounts Receivable | $802.69K | 3.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $102.84K | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Gain Therapeutics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gain Therapeutics Inc's current assets represent 97.5% of total assets in 2025, an increase from 60.9% in 2018.
- Cash Position: Cash and equivalents constituted 91.3% of total assets in 2025, up from 49.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 3.5% of total assets.
Gain Therapeutics Inc Competitors by Total Assets
Key competitors of Gain Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Gain Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.69 | 2.22 | 18.08 |
| Quick Ratio | 4.69 | 2.22 | 18.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.34 Million | $6.12 Million | $41.85 Million |
Gain Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Gain Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.19 |
| Latest Market Cap to Assets Ratio | 2.15 |
| Asset Growth Rate (YoY) | 88.2% |
| Total Assets | $22.82 Million |
| Market Capitalization | $49.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Gain Therapeutics Inc's assets at a significant premium (2.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Gain Therapeutics Inc's assets grew by 88.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gain Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Gain Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.82 Million | +88.22% |
| 2024-12-31 | $12.12 Million | -34.85% |
| 2023-12-31 | $18.61 Million | -22.78% |
| 2022-12-31 | $24.10 Million | -38.18% |
| 2021-12-31 | $38.99 Million | +305.91% |
| 2020-12-31 | $9.60 Million | +1354.58% |
| 2019-12-31 | $660.29K | -18.65% |
| 2018-12-31 | $811.63K | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more